Phases, active trials: Phase 1: 45, Phase 1/2: 12, Phase 2: 28, Phase 2/3: 7, Phase 3: 73, Phase 4: 6, No phase listed: 35
Following the separation of the consumer business, Johnson & Johnson's pharmaceutical arm (Janssen) operates one of the strongest oncology and immunology pipelines in the industry. In hematology, Darzalex (daratumumab) for multiple myeloma continues expanding into earlier lines and new combinations, while Carvykti (ciltacabtagene autoleucel), the BCMA CAR-T therapy, advances into earlier myeloma settings. Rybrevant (amivantamab), the EGFR-MET bispecific antibody for NSCLC, is rapidly expanding with combination programs including lazertinib. In prostate cancer, Erleada (apalutamide) and Akeega (niraparib/abiraterone) address different molecular subgroups. Their immunology pipeline spans Stelara (ustekinumab), Tremfya (guselkumab), and a next-generation IL-23/IL-17 portfolio.
- Hematology (multiple myeloma, CAR-T)
- Thoracic oncology (EGFR-MET bispecific)
- Prostate cancer
- Immunology / dermatology (IL-23, IL-17)
- Solid tumor immuno-oncology
- Darzalex (daratumumab): CD38, multiple myeloma
- Carvykti (ciltacabtagene autoleucel): BCMA CAR-T
- Rybrevant (amivantamab): EGFR-MET bispecific, NSCLC
- Erleada (apalutamide): non-metastatic/metastatic CRPC
- Akeega (niraparib + abiraterone): HRR-mutated prostate
- Tremfya (guselkumab): IL-23p19, psoriasis/IBD
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) NCT04811560 | Primary completion moved at least 1 year 10 months later | Recruiting |
15 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic… NCT07230860 | Nov 19, 2026 · Estimated | Phase 2 |
15 more on the Completions page. See the calendar →
Monitor the Johnson & Johnson / Janssen pipeline daily
Get a daily digest when Johnson & Johnson / Janssen registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Multiple Myeloma | 27 |
| Colitis, Ulcerative | 17 |
| Prostatic Neoplasms | 14 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Crohn Disease | 13 |
| Arthritis, Psoriatic | 12 |
| Crohn's Disease | 7 |
| Lymphoma, Non-Hodgkin | 7 |
J&J's Rybrevant + lazertinib combination represents the most significant competitive threat to Tagrisso (osimertinib) in EGFR-mutant NSCLC. Any company active in lung cancer or multiple myeloma must monitor Janssen's Phase 3 pipeline in those indications.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Johnson & Johnson / Janssen's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Johnson & Johnson / Janssen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Johnson & Johnson / Janssen pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Nipocalimab in Moderate to Severe Sjogren's Disease NCT06741969 | Active, Not Recruiting | Primary completion moved earlier from Jan 1, 2028 to Feb 4, 2027 | 2026-11-13 |
| A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder… NCT07735793 | Recruiting | Start date changed from estimate of Sep 30, 2026 to Oct 12, 2026 | 2026-11-10 |
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) NCT04811560 | Recruiting | Primary completion pushed from Feb 26, 2027 to Dec 29, 2028 | 2026-11-05 |
| A Study of Varipulse Catheter in Participants With Paroxysmal Atrial… NCT07511166 | Recruiting | Recruitment opened | 2026-11-05 |
| A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of… NCT05912517 | Recruiting | Trial sites expanded: 65 → 69 locations | 2026-11-04 |
Each trial page shows every change DataLookout has recorded for that trial.